Rebecca J. Fairclough
BioPharmaceuticals R&D, AstraZeneca
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Compromised chronic efficacy of a glucokinase activator AZD1656 in mouse models for common human GCKR variants.
Journal: Biochemical pharmacology
Published: May 15, 2024
The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs1260326.
Journal: Molecular metabolism
Published: March 07, 2023
Clinic-ready inhibitor of MMP-9/-12 restores sensory and functional decline in rodent models of spinal cord injury.
Journal: Clinical and translational medicine
Published: April 05, 2022
Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial.
Journal: European journal of endocrinology
Published: November 30, 2021
Effect of AZD4017, a Selective 11β-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal Osteopenia.
Journal: The Journal of clinical endocrinology and metabolism
Published: October 18, 2021
Public-Private Partnerships: Compound and Data Sharing in Drug Discovery and Development.
Journal: SLAS discovery : advancing life sciences R & D
Published: February 15, 2021
Discovery and mechanism of action studies of 4,6-diphenylpyrimidine-2-carbohydrazides as utrophin modulators for the treatment of Duchenne muscular dystrophy.
Journal: European journal of medicinal chemistry
Published: December 01, 2020
11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension.
Journal: The Journal of clinical endocrinology and metabolism
Published: June 15, 2020
Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge.
Journal: Diabetes, obesity & metabolism
Published: April 07, 2020
11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial.
Journal: Brain communications
Published: September 01, 2019
Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches.
Journal: Nature reviews. Genetics
Published: April 24, 2013
Pharmacologically targeting the primary defect and downstream pathology in Duchenne muscular dystrophy.
Journal: Current gene therapy
Published: February 15, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026